Read by QxMD icon Read

cancer nanomedicine

Liuqi Peng, Xuan Mei, Jun He, Jiekun Xu, Weiku Zhang, Ruizheng Liang, Min Wei, David G Evans, Xue Duan
2D nanomaterials have attracted considerable research interest in drug delivery systems, owing to their intriguing quantum size and surface effect. Herein, Gd3+ -doped monolayered-double-hydroxide (MLDH) nanosheets are prepared via a facile bottom-up synthesis method, with a precisely controlled composition and uniform morphology. MLDH nanosheets as drug carrier are demonstrated in coloading of doxorubicin and indocyanine green (DOX&ICG), with an ultrahigh drug loading content (LC) of 797.36% and an encapsulation efficiency (EE) of 99...
March 14, 2018: Advanced Materials
Bo Zhang, Honglan Wang, Ting Jiang, Kai Jin, Zimiao Luo, Wei Shi, Heng Mei, Huafang Wang, Yu Hu, Zhiqing Pang, Xinguo Jiang
As one of the most intractable tumors, pancreatic ductal adenocarcinoma (PDA) has a dense extracellular matrix (ECM) which could increase solid stress within tumors to compress tumor vessels, reduce tumor perfusion, and compromise nanomedicine delivery for PDA. Thus, alleviating solid stress represents a potential therapeutic target for PDA treatment. In this study, cyclopamine, a special inhibitor of the hedgehog signaling pathway which contributes a lot to ECM formation of PDA, was exploited to alleviate solid stress and improve nanomedicine delivery to PDA...
March 13, 2018: Journal of Drug Targeting
Heerak Chugh, Damini Sood, Ishita Chandra, Vartika Tomar, Gagan Dhawan, Ramesh Chandra
Development of nanoparticles (NPs) as a part of cancer therapeutics has given rise to a new field of research - cancer nanomedicine. In comparison to traditional anti-cancer drugs, NPs provide a targeted approach which prevents undesirable effects. In this communication, we have reviewed the role of gold and silver NPs (AgNPs) in the cancer nanomedicine. The preparation of gold NPs (AuNPs) and AgNPs can be grouped into three categories - physical, chemical and biological. Among the three approaches, the biological approach is growing and receiving more attention due to its safe and effective production...
March 13, 2018: Artificial Cells, Nanomedicine, and Biotechnology
Rui Huang, Jiawei Li, Dereje Kebebe, Yumei Wu, Bing Zhang, Zhidong Liu
Tumor-targeted delivery is considered a crucial component of current anticancer drug development and is the best approach to increase the efficacy and reduce the toxicity. Nanomedicine, particularly ligand-based nanoparticles have shown a great potential for active targeting of tumor. Cell penetrating peptide is one of the promising ligands in a targeted cancer therapy. In this study, the gambogic acid-loaded nanostructured lipid carrier (GA-NLC) was modified with two kinds of cell penetrating peptides (cRGD and RGERPPR)...
November 2018: Drug Delivery
Pravin Bhattarai, Sadaf Hameed, Zhifei Dai
Angiogenesis is a normal physiological remodeling process initiated at the time of embryonic development and lessened with the progress of time. Nevertheless, continuous activation of stringent signaling pathways and proangiogenic factors during tumorigenesis (a pathological condition) instigates serious vessel abnormalities eliciting severe therapeutic inefficiency. In principle, systemic delivery of robust antiangiogenic drugs often fails to reach these abnormal tumor vessels depicting poor pharmacokinetics, biodistribution profiles and adverse side effects in vivo...
March 12, 2018: Nanoscale
Zhao Xiaoxiong, Wang Junmei, Song Yujun, Xinhua Chen
A new methodology has been developed with conjugating nanoparticles (NPs) with an active ingredient of Chinese herbs for nanomedicines with auto-targeting and enhanced magnetic resonance imaging (MRI) for liver cancer therapy. Fe@Fe3 O4 NPs are first synthesized via the programmed microfluidic process, whose surfaces are first modified with -NH2 groups using a silane coupling technique that uses (3-aminopropyl) trimethoxysilane (APTMS) as the coupling reagent and are subsequently activated by the bifunctional amine-active cross-linker (e...
March 12, 2018: Drug Development and Industrial Pharmacy
Kelly R Rhodes, Jordan J Green
Exciting developments in cancer nanomedicine include the engineering of nanocarriers to deliver drugs locally to tumors, increasing efficacy and reducing off-target toxicity associated with chemotherapies. Despite nanocarrier advances, metastatic cancer remains challenging to treat due to barriers that prevent nanoparticles from gaining access to remote, dispersed, and poorly vascularized metastatic tumors. Instead of relying on nanoparticles to directly destroy every tumor cell, immunotherapeutic approaches target immune cells to train them to recognize and destroy tumor cells, which, due to the amplification and specificity of an adaptive immune response, may be a more effective approach to treating metastatic cancer...
March 7, 2018: Molecular Immunology
Aditi Jhaveri, Pranali Deshpande, Bhushan Pattni, Vladimir Torchilin
Glioblastomas (GBMs) are highly aggressive brain tumors with a very grim prognosis even after multi-modal therapeutic regimens. Conventional chemotherapeutic agents frequently lead to drug resistance and result in severe toxicities to non-cancerous tissues. Resveratrol (RES), a natural polyphenol with pleiotropic health benefits, has proven chemopreventive effects in all the stages of cancer including initiation, promotion and progression. However the poor physico-chemical properties of RES severely limit its use as a free drug...
March 6, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
Si-Yong Qin, Yin-Jia Cheng, Zhi-Wei Jiang, Yi-Han Ma, Ai-Qing Zhang
The morphology of nanomedicines has a large influence on the anticancer efficiency of therapeutic agents in biological systems. In this study, camptothecin (CPT)-based nanodrugs with helical and spherical shapes were simply built without the need of any additional carriers. Self-deliverable spherical nanodrug represented a therapeutic advantage over the helical one, which was uncovered from the in vitro toxicity assay. Confocal imaging study indicated that the better outcome of spherical nanodrug was ascribed to the faster cellular uptake...
February 24, 2018: Colloids and Surfaces. B, Biointerfaces
Wenpei Fan, Bryant C Yung, Xiaoyuan Chen
Featuring high biocompatibility, the emerging field of gas therapy has attracted extensive attention in the medical and scientific communities. Currently, considerable research has focused on nitric oxide (NO) gasotransmitter due to its unparalleled dual roles in directly killing cancer cells at high concentrations and cooperatively sensitizing cancer cells to other treatments for synergistic therapy. Of particular note, recent state-of-the-art studies have turned our attention to the chemical design of various endogenous/exogenous stimuli-responsive NO releasing nanomedicines and their biomedical applications for on-demand NO-sensitized synergistic cancer therapy, which have been systemically discussed in this minireview...
March 8, 2018: Angewandte Chemie
Hsiang-I Tsai, Lijuan Jiang, Xiaowei Zeng, Hongbo Chen, Zihuang Li, Wei Cheng, Jinxie Zhang, Jie Pan, Dong Wan, Li Gao, Zhenhua Xie, Laiqiang Huang, Lin Mei, Gan Liu
The clinical applications of platinum-based antitumor agents are still largely limited by severe side effects as well as multidrug resistance (MDR). To solve these problems, we developed an 1,2-diaminocyclohexane-platinum(II) (DACHPt)-loaded nanoparticle (NP-TPGS-Pt) by self-assembly of poly(amidoamine)-polyglutamic acid- b -D-α-tocopheryl polyethylene glycol 1000 succinate (PAM-PGlu- b -TPGS) and DACHPt. NP-TPGS-Pt showed robust stability and pH-responsive DACHPt release profile in vitro similar to the PEG-containing nanoparticle (NP-PEG-Pt)...
2018: Frontiers in Pharmacology
Mengqun Yao, Yinchu Ma, Hang Liu, Malik Ihsanullah Khan, Song Shen, Shuya Li, Yangyang Zhao, Yi Liu, Guoqing Zhang, Xiaoqiu Li, Fei Zhong, Wei Jiang, Yucai Wang
Multidrug resistance (MDR) is the major cause for chemotherapy failure, which constitutes a formidable challenge in the field of cancer therapy. The synergistic chemo-photothermal treatment has been reported to be a potential strategy to overcome MDR. In this work, rationally designed enzyme-degradable, hyperbranched polyphosphoester nanomedicines were developed for reversing MDR via the co-delivery of doxorubicin and IR-780 (hPPEDOX&IR) as combined chemo-photothermal therapy. The amphiphilic hyperbranched polyphosphoesters with phosphate bond as the branching point were synthesized via a simple but robust one-step polycondensation reaction...
March 7, 2018: Biomacromolecules
Yasar Hoosen, Priyamvada Pradeep, Pradeep Kumar, Lisa C du Toit, Yahya E Choonara, Viness Pillay
Ovarian cancer (OC) has gained a great deal of attention due to its aggressive proliferative capabilities, high death rates and poor treatment outcomes, rendering the disease the ultimate lethal gynaecological cancer. Nanotechnology provides a promising avenue to combat this malignancy by the niche fabrication of optimally-structured nanomedicines that ensure potent delivery of chemotherapeutics to OC, employing nanocarriers to act as "intelligent" drug delivery vehicles, functionalized with active targeting approaches for precision delivery of chemotherapeutics to overexpressed biomarkers on cancer cells...
March 4, 2018: International Journal of Molecular Sciences
Jingrong Zhou, Gan Tian, Lijuan Zeng, Xueer Song, Xiu-Wu Bian
Owing to the progressive development of metal-organic frameworks (MOFs) synthetic processes and their unique characters associated with the excellent performance-selectable composition, tunable pore scale, large surface area, and good thermal stability, MOFs have captured the interest and the imagination of an increasing number of scientists working in different fields. In the area of biomedical applications, MOFs are especially involved in sensing, molecular imaging, and drug delivery, with strong contributions to the whole nanomedicine area...
March 6, 2018: Advanced Healthcare Materials
Peng Guo, Biran Wang, Daxing Liu, Jiang Yang, Kriti Subramanyam, Craig McCarthy, Jacob Hebert, Marsha A Moses, Debra Auguste
Atomic force microscopy (AFM) is a powerful tool to detect in vitro antibody-antigen interactions. To date, however, AFM-measured antibody-antigen interactions have yet to be exploited to predict in vivo tumor specificity of antibody-directed nanomedicines. In this study, we have utilized AFM to directly measure the biomechanical interaction between live triple negative breast cancer (TNBC) cells and an antibody against ICAM1, a recently identified TNBC target and, for the first time, provide the proof-of-principle evidence that this in vitro live TNBC cell-ICAM1 antibody binding force measured by AFM more precisely correlates with the improved in vivo tumor accumulation and therapeutic efficacy of ICAM1 antibody-directed liposomes than ICAM1 gene and surface protein overexpression levels in an orthotopic TNBC model...
March 5, 2018: Nano Letters
Xiaoyan Yang, Gongyuan Liu, Yunhao Shi, Wei Huang, Jinjun Shao, Xiaochen Dong
Black phosphorus (BP), emerging as a new member of two-dimensional nanomaterials, has attracted growing research interests for its amazing photoelectric properties and promising application in electronic devices. Recently, BP has been confirmed to be a desirable candidate for phototherapy against cancer, including photothermal therapy (PTT) and photodynamic therapy (PDT). By regulating the number of layers, the bandgap of BP nanosheets (NSs) can be finely tuned to present near infrared light triggered phototherapeutic behaviors...
March 5, 2018: Nanotechnology
Xuejia Kang, Zening Zheng, Zehua Liu, Huiyuan Wang, Yuge Zhao, Wenyuan Zhang, Mingjie Shi, Yang He, Yang Cao, Qin Xu, Chengyuan Peng, Yongzhuo Huang
Effective treatment of metastatic (stage IV) breast cancers remains a formidable challenge. To address this issue, a cell-penetrating peptide-assisted liposomal system was developed for codelivery of doxorubicin and andrographolide. This nanomedicine-based combination therapy showed the ability to inhibit the in vitro migration and invasion of 4T1 cells through the wound healing and transwell invasion assays. Furthermore, this delivery system exhibited the enhanced accumulation in the tumor tissues and deep intratumoral penetration...
March 2, 2018: Molecular Pharmaceutics
Khaled Greish, Aanchal Mathur, Moiz Bakhiet, Sebastien Taurin
By the end of 2017 more than 200,000 scientific research articles had been published about nanomedicine. Out of this vast number only a few of the reported nanoconstructs reached clinical trials for various applications, including the diagnosis and treatment of several cancers, and the treatment of infections and other non-cancerous diseases. 30 years after the pioneering work in this field of research, the low product yield at the end of research pipeline leads to a question that is asked by many: 'had nanomedicine been lost in translation?' In this review, we will discuss the landscape of nanomedicine regarding cancer treatment and miscellaneous applications as well as some obstacles toward full utilization of this powerful therapeutic tool and suggest a few solutions to improve the current translational value of nanomedicine research...
March 2, 2018: Therapeutic Delivery
Anna Cifuentes-Rius, Lisa M Butler, Nicolas H Voelcker
No abstract text is available yet for this article.
February 27, 2018: Nanomedicine
Naris Nilubol, ZiQiang Yuan, Giulio F Paciotti, Lawrence Tamarkin, Carmen Sanchez, Kelli Gaskins, Esther M Freedman, Shugeng Cao, Jielu Zhao, David G I Kingston, Steven K Libutti, Electron Kebebew
Background: The advantages of nanomedicines include preferential delivery of the payload directly to tumor tissues. CYT-21625 is the novel, first-in-class gold nanomedicine designed to target tumor vasculature and cancer cells by specifically delivering recombinant human tumor necrosis factor alpha (rhTNF) and a paclitaxel prodrug. Methods: We analyzed TNF receptor expression in publicly available gene expression profiling data and in thyroid tissue samples. Mice with metastatic FTC-133 and 8505C xenografts and the MEN1 conditional knock-out mice were treated weekly with CYT-21625 and gold nanoparticles with rhTNF only (CYT-6091); controls included mice treated with either paclitaxel or saline...
February 22, 2018: Journal of the National Cancer Institute
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"